StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.51+0.22 (+1.66%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Trevi Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Trevi Therapeutics's price to book ratio was 6.6× on Nov 11, 2026, against 8.9× a year earlier. Over the last 5 years it ranged from 0.8× to 13.9×, with a median of 3.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.6×−1.9
2025Dec 31, 20258.5×+3.2
2024Dec 31, 20245.3×+4.3
2023Dec 29, 20231.0×−0.1
2022Dec 30, 20221.0×−0.3
2021Dec 31, 20211.3×+0.0
2020Dec 31, 20201.2×+0.1
2019Dec 31, 20191.1×–

More Trevi Therapeutics figures

See a number that looks wrong?